Impact of high neutrophil-to-lymphocyte ratio on the cardiovascular benefit of PCSK9 inhibitors in familial hypercholesterolemia subjects with atherosclerotic cardiovascular disease: real-world data from two lipid units

2021 ◽  
Author(s):  
Roberto Scicali ◽  
Giuseppe Mandraffino ◽  
Antonino Di Pino ◽  
Michele Scuruchi ◽  
Viviana Ferrara ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Familial Hypercholesterolemia ◽  
Real World ◽  
Neutrophil To Lymphocyte Ratio ◽  
Atherosclerotic Cardiovascular Disease ◽  
Pcsk9 Inhibitors ◽  
Real World Data ◽  
World Data ◽  
Lymphocyte Ratio ◽  
Cardiovascular Benefit

Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients

2018 ◽  
Vol 71 (12) ◽  
pp. 1010-1017 ◽  
Author(s):  
Alberto Zamora ◽  
Luís Masana ◽  
Marc Comas-Cufi ◽  
Núria Plana ◽  
Àlex Vila ◽  
...  
Keyword(s):  
Real World ◽  
Pcsk9 Inhibitors ◽  
Real World Data ◽  
World Data ◽  
Number Of Patients

scholarly journals Real-world use of PCSK9 inhibitors: A single-center experience

2018 ◽  
Vol 47 (1) ◽  
pp. 265-270 ◽  
Author(s):  
Sinan Sarsam ◽  
Abeer Berry ◽  
George Degheim ◽  
Robby Singh ◽  
Marcel Zughaib
Keyword(s):  
Cardiovascular Disease ◽  
Lipid Profile ◽  
Real World ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Atherosclerotic Cardiovascular Disease ◽  
Pcsk9 Inhibitors ◽  
Pcsk9 Inhibitor ◽  
The Impact

Objective Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease. Many patients are intolerant to or have limited benefit from statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been approved for treating hyperlipidemia in these patients. We sought to investigate the impact of these medications in a real-world cardiology practice. Methods This was a retrospective study of 17 patients with either heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol (LDL-C) levels above the treatment target despite maximally tolerated statins. Baseline lipid profile was compared with a repeat lipid profile obtained 4 to 6 weeks after initiating treatment with a PCSK9 inhibitor. Results The average duration of PCSK9 inhibitor treatment was 10.7 months. Lipid profile comparison showed that total cholesterol decreased from 243 ± 72 to 148 ± 39 (mg/dL) (39% reduction), triglycerides decreased from 185 ± 86 to 149 ± 62 (mg/dL) (19.5% reduction), high-density lipoprotein cholesterol increased from 56 ± 20 to 62 ± 26 (mg/dL) (10.7% increase), and LDL-C decreased from 154 ± 30 to 57 ± 32 (mg/dL) (63% reduction) from baseline. Conclusions PCSK9 inhibitors as add-on therapy to maximally tolerated statins resulted in an approximately 63% reduction in LDL-C.

scholarly journals Neutrophil/lymphocyte ratio in metastatic colorectal cancer: real-world data for evidence of its prognostic role

2019 ◽  
Vol 30 ◽  
pp. iv18
Author(s):  
G. Nogueira-Costa ◽  
I. Fernandes ◽  
N. Guerra-Pereira ◽  
R. Gameiro ◽  
J. Gramaça ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Real World ◽  
Prognostic Role ◽  
Real World Data ◽  
World Data ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio

scholarly journals The Use of Real-World Data to Evaluate the Association Between Atopic Dermatitis and Cardiovascular Disease: A Retrospective Claims Analysis

2021 ◽  
Vol 11 (5) ◽  
pp. 1707-1715
Author(s):  
Jashin J. Wu ◽  
Caroline Amand ◽  
Daniel J. No ◽  
Puneet Mahajan ◽  
Abhijit Gadkari ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Atopic Dermatitis ◽  
Real World ◽  
Claims Analysis ◽  
Real World Data ◽  
World Data
Sign in / Sign up

Export Citation Format

Share Document